Research Article
Development and Evaluation of a Novel Cuproptosis-Related lncRNA Signature for Gastric Cancer Prognosis
Table 1
The clinical features between the training and test cohorts.
| | Covariates | Type | Total | Test | Train | value |
| | Age | <=65 | 163 (43.94%) | 70 (47.3%) | 93 (41.7%) | 0.3471 | | >65 | 205 (55.26%) | 77 (52.03%) | 128 (57.4%) | | Unknown | 3 (0.81%) | 1 (0.68%) | 2 (0.9%) |
| | Gender | Female | 133 (35.85%) | 58 (39.19%) | 75 (33.63%) | 0.3259 | | Male | 238 (64.15%) | 90 (60.81%) | 148 (66.37%) |
| | Grade | G1 | 10 (2.7%) | 5 (3.38%) | 5 (2.24%) | 0.7846 | | G2 | 134 (36.12%) | 53 (35.81%) | 81 (36.32%) | | G3 | 218 (58.76%) | 85 (57.43%) | 133 (59.64%) | | Unknown | 9 (2.43%) | 5 (3.38%) | 4 (1.79%) |
| | Stage | Stage I | 50 (13.48%) | 17 (11.49%) | 33 (14.8%) | 0.7499 | | Stage II | 111 (29.92%) | 42 (28.38%) | 69 (30.94%) | | Stage III | 149 (40.16%) | 60 (40.54%) | 89 (39.91%) | | Stage IV | 38 (10.24%) | 17 (11.49%) | 21 (9.42%) | | Unknown | 23 (6.2%) | 12 (8.11%) | 11 (4.93%) |
| | T | T1 | 18 (4.85%) | 8 (5.41%) | 10 (4.48%) | 0.9247 | | T2 | 78 (21.02%) | 31 (20.95%) | 47 (21.08%) | | T3 | 167 (45.01%) | 67 (45.27%) | 100 (44.84%) | | T4 | 100 (26.95%) | 37 (25%) | 63 (28.25%) | | Unknown | 8 (2.16%) | 5 (3.38%) | 3 (1.35%) |
| | M | M0 | 328 (88.41%) | 129 (87.16%) | 199 (89.24%) | 0.3012 | | M1 | 25 (6.74%) | 13 (8.78%) | 12 (5.38%) | | Unknown | 18 (4.85%) | 6 (4.05%) | 12 (5.38%) |
| | N | N0 | 108 (29.11%) | 36 (24.32%) | 72 (32.29%) | 0.4562 | | N1 | 97 (26.15%) | 39 (26.35%) | 58 (26.01%) | | N2 | 74 (19.95%) | 32 (21.62%) | 42 (18.83%) | | N3 | 74 (19.95%) | 32 (21.62%) | 42 (18.83%) | | Unknown | 18 (4.85%) | 9 (6.08%) | 9 (4.04%) |
|
|
